Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival

Fig. 2

Methylation profile of 200 probes at diagnosis allow distinguishing responders and non-responders to azacitidine (AZA) treatment. Heatmap showing the hierarchical clusterization of the 200 probes obtained with combined rank analysis that are differentially methylated between responders and non-responders in bone marrow samples at diagnosis. Selected genes associated with differentially methylated CpGs are indicated

Back to article page
\